GILD
30 S&P 500 Stocks That Rose In The Crisis: It’s A Market Of Stocks: Part 1
2020-04-23
S&P 500 Stocks I have long asserted that it is a market of stocks and not a stock market. Perhaps the veracity of that statement has never been clearer than it is today. We are all aware of the devastation to the stock market in general that the shutdown instigated by the coronavirus has cost. […]
Finding Value In The S&P 500: 9 Healthcare Dividend Growth Stocks: Part 1
2016-08-04
Introduction Most everyone would agree that the stock market as measured by the S&P 500 is not cheap today. However, there might be a great deal of disagreement regarding precisely how overvalued the S&P 500 currently is. Nevertheless, I would agree that in the general sense, stocks are not exactly bargains today. This might especially […]
12 Attractive Fast-Growing Dividend Growth Stocks for High Total Return
2015-08-27
Introduction The current market environment is presenting many challenges to the conservative retired investor in need of current income. Interest rates are near all-time lows and the valuations of many blue-chip dividend growth stocks have become extended. Consequently, it is becoming very difficult to find quality investment opportunities that can provide safety through sound valuation, […]
Stocks 2014: Investing for Growth – The Power and Protection of High Compounding Earnings Growth – Part 2
2013-01-16
As I become more mature (translate: gotten older), my investment philosophy has slowly evolved into a more conservative posture. When I was a younger investor I felt I had time on my side, and therefore, was willing to take on greater risk as long as I believed that greater rewards could follow. In other words, […]
Gilead Sciences Inc: Strong Growth At An Unreasonably Low Price
2012-05-21
Gilead Sciences Inc (GILD) is an innovative healthcare company with a strong record of historical earnings growth and expectations for above-average growth into the future. Nevertheless, Mr. Market seems unwilling to recognize the past and future earnings power of this niche pharmaceutical growth stock. Consequently, the company trades at a single digit PE ratio that […]